Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Kymera Therapeutics ( (KYMR) ) is now available.
On June 26, 2025, Kymera Therapeutics announced an underwritten public offering of its common stock and pre-funded warrants, expected to raise approximately $237.3 million, with the potential to increase to $272.7 million if underwriters exercise their options fully. The proceeds will be used to advance Kymera’s clinical and preclinical degrader programs and for general corporate purposes. The offering is anticipated to close on June 30, 2025, subject to customary conditions, and is part of Kymera’s strategy to fund operations into mid-2028.
The most recent analyst rating on (KYMR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.
Spark’s Take on KYMR Stock
According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.
Kymera Therapeutics benefits from strong technical momentum and strategic corporate partnerships, which enhance its growth outlook despite current financial challenges. The company’s substantial cash reserves and promising pipeline developments further support future potential, although the negative cash flow and earnings remain significant risks.
To see Spark’s full report on KYMR stock, click here.
More about Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biotechnology company focused on developing targeted protein degradation (TPD) therapies. These therapies aim to address critical health issues, particularly in immunological diseases, by targeting disease pathways that are inaccessible with conventional treatments. The company is building a pipeline of oral small molecule degraders to provide effective therapies for patients.
Average Trading Volume: 904,481
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.03B
For a thorough assessment of KYMR stock, go to TipRanks’ Stock Analysis page.